Belgium· BE-AMP-SAM534720-00
Yescarta 0,4–2 x 10*8 cells
A axicabtagene ciloleucel product containing axicabtagene ciloleucel, registered in Belgium by Kite Pharma EU. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Axicabtagene ciloleucel is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XL03 (axicabtagene ciloleucel), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Axicabtagene ciloleucel · ATC L01XL03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Axicabtagene Ciloleucel
- Manufacturer
- Kite Pharma EU
- Country
- Belgium (BE)
- ATC code
- L01XL03
- ATC class
- Axicabtagene ciloleucel
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 5
- be_apb7740558
- be_apb7729437
- be_apb7729452
- be_apb7729445
- be_apb3814431
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
58 interactions on record for axicabtagene ciloleucel.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Axicabtagene ciloleucel · interactions on record
58 records
- 28 severe
- 30 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Axicabtagene ciloleucel in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesYESCARTAKite Pharma, Inc.
- SwitzerlandYescartaGilead Sciences Switzerland Sàrl
- CzechiaYESCARTAKite Pharma EU B.V., Hoofddorp
- SpainYESCARTA 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONKite Pharma Eu B.V.
- FinlandYescartaKite Pharma EU B.V.
- FranceYESCARTA 0,4 - 2 x 100 000 000 cellules, dispersion pour perfusionKITE PHARMA EU (PAYS-BAS)
- United KingdomYescarta 40million-200million cells/68ml dispersion for infusion bagsGilead Sciences Ltd
- CanadaYESCARTAGILEAD SCIENCES CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yescarta
- Liechtenstein · Yescarta
- Norway · Yescarta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/82da4c5b-47a3-4cf2-bc8c-294d3ac71d65 GET /v1/drugs/82da4c5b-47a3-4cf2-bc8c-294d3ac71d65?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Yescarta 0,4–2 x 10*8 cells",
"name_fr": "Yescarta 0,4–2 x 10*8 cells",
"name_nl": "Yescarta 0,4–2 x 10*8 cells",
"amp_code": "SAM534720-00",
"strengths": [
"300.0000"
],
"pack_count": 1,
"substances": [
"Axicabtagene Ciloleucel",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Axicabtagene Ciloleucel",
"authorisation_numbers": [
"EU/1/18/1299/001"
]
}See everything about axicabtagene ciloleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.